Kinimmune Wins Highly Competitive Nci Funding To Advance Solid Tumor Immunotherapy For Patients Refractory To Checkpoint Inhibitors
Nov 09, 2022•over 2 years ago
Description
Kinimmune, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced that the company has received $400k in funding from the National Cancer Institute (NCI) at the National Institutes of Health for its Phase I STTR application, “Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers”. This award will advance the preclinical development of KIN-102, an immunostimulant for intratumoral injection that is designed to turn ‘cold’ tumors ‘hot’ for synergy with immuno-oncology drugs such as checkpoint inhibitors.
FundzWatch™ Score
74
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood